Identification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Study

Basit Öğe Kaydı
dc.authoridRahbar Saadat, Yalda/0000-0002-3295-404X
dc.authorwosidRahbar Saadat, Yalda/O-8109-2017
dc.contributor.authorHekmatshoar, Yalda
dc.contributor.authorRahbar Saadat, Yalda
dc.contributor.authorOzkan, Tulin
dc.contributor.authorBozkurt, Sureyya
dc.contributor.authorKaradag Gurel, Aynur
dc.date.accessioned2024-05-19T14:40:05Z
dc.date.available2024-05-19T14:40:05Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractImatinib (IMA) and nilotinib are the first and second generations of BCR-ABL tyrosine kinase inhibitors, which widely applied in chronic myeloid leukemia (CML) treatment. Here we aimed to provide new targets for CML treatment by transcriptome analysis. Microarray data GSE19567 was downloaded and analyzed from Gene Expression Omnibus (GEO) to identify common genes, which are downregulated or upregulated in K562-imatinib and K562-nilotinib treated cells. The differentially expressed genes (DEGs) were assessed, and STRING and Cytoscape were used to create the protein-protein interaction (PPI) network. In imatinib and nilotinib treated groups' comparison, there were common 626 upregulated and 268 downregulated genes, which were differentially expressed. The GO analysis represented the enrichment of DEGs in iron ion binding, protein tyrosine kinase activity, transcription factor activity, ATP binding, sequence-specific DNA binding, cytokine activity, the mitochondrion, sequence-specific DNA binding, plasma membrane and cell-cell adherens junction. KEGG pathway analysis revealed that downregulated DEGs were associated with pathways including microRNAs in cancer and PI3K-Akt signaling pathway. Furthermore, upregulated DEGs were involved in hematopoietic cell lineage, lysosome and chemical carcinogenesis. Among the upregulated genes, MYH9, MYH14, MYL10, MYL7, MYL5, RXRA, CYP1A1, FECH, AKR1C3, ALAD, CAT, CITED2, CPT1A, CYP3A5, CYP3A7, FABP1, HBD, HMBS and PPOX genes were found as hub genes. Moreover, 20 downregulated genes, YARS, AARS, SARS, GARS, CARS, IARS, RRP79, CEBPB, RRP12, UTP14A, PNO1, CCND1, DDX10, MYC, WDR43, CEBPG, DDIT3, VEGFA, PIM1 and TRIB3 were identified as hub genes. These genes have the potential to become target genes for diagnosis and therapy of CML patients.en_US
dc.identifier.doi10.1080/15257770.2023.2296021
dc.identifier.issn1525-7770
dc.identifier.issn1532-2335
dc.identifier.pmid38117080en_US
dc.identifier.scopus2-s2.0-85180168402en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org10.1080/15257770.2023.2296021
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4903
dc.identifier.wosWOS:001128390300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofNucleosides Nucleotides & Nucleic Acidsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectImatiniben_US
dc.subjectNilotiniben_US
dc.subjectBioinformaticsen_US
dc.subjectGeoen_US
dc.subjectGene Expressionen_US
dc.titleIdentification of common genes and pathways underlying imatinib and nilotinib treatment in CML: a Bioinformatics Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu